This prospective, noninterventional study evaluates the effectiveness, tolerability, safety and quality of life following 450 patients with mRCC starting either on pazopanib as first-line therapy or third-line everolimus plus/minus lenvatinib following nivolumab.
Browsing: Disease Area > Genitourinary
Lydia Makaroff of the European Cancer Patient Coalition (ECPC, Brussels, Belgium) speaks with Oncology Central about the goals and upcoming projects for the ECPC in 2017.
What advances have been made in immune therapy for renal cell carcinoma? Discover what the experts say in this opinion article from Future Oncology.
New clinical trial data indicates that pembrolizumab immunotherapy both significantly increases survival in bladder cancer and has activity against mucosal melanoma.
This research article investigates practice trends in the use of surgical resection versus thermal ablation for the management of early stage renal cell carcinoma with regard to sociodemographic factors and associated outcome.
A review of the some of the most recent available data for immune checkpoint inhibitors for patients with renal cell carcinoma.
Owing to the wide variation in the incidence of toxicity in patients treated with sorafenib, this primary paper details a study investigating the potential role of genetic polymorphisms in the incidence of side effects.
The authors review standard practices, current trends and controversies, and promising future therapies in muscle-invasive and metastatic bladder urothelial cancers.